How Does Pfizer Stock Stack Up Against Its Peers?
Here is how Pfizer (PFE) stock stacks up against its peers in size, valuation, growth and margin.
- PFE’s operating margin of 24.6% is high, lower than most peers – trailing LLY (43.0%).
- PFE’s revenue growth of 3.9% in the last 12 months is low, lagging LLY, JNJ but outpacing MRK, BMY.
- PFE’s stock is down 4.5% in last 1 year, and trades at a PE of 14.1; it underperformed LLY, JNJ.
As a quick background, Pfizer provides biopharmaceutical products, including medicines, vaccines, and biosimilars for cardiovascular, metabolic, women’s health, and chronic immune and inflammatory diseases.
A single stock can be risky, but there is a huge value to a broader, diversified approach. If you seek an upside with less volatility than holding an individual stock, consider the Trefis High Quality Portfolio (HQ). HQ has outperformed its benchmark — a combination of S&P 500, Russell, and S&P midcap index — and achieved returns exceeding 91% since its inception. Risk management is key — consider what the long-term portfolio performance could be if you blended 10% commodities, 10% gold, and 2% crypto with HQ’s performance metrics.
| PFE | LLY | JNJ | MRK | BMY | |
|---|---|---|---|---|---|
| Market Cap ($ Bil) | 138.8 | 841.7 | 450.3 | 214.0 | 94.9 |
| Revenue ($ Bil) | 62.8 | 53.3 | 92.1 | 64.2 | 48.0 |
| PE Ratio | 14.1 | 61.0 | 17.9 | 11.2 | 15.7 |
| LTM Revenue Growth | 3.9% | 36.8% | 5.1% | 1.7% | 1.3% |
| LTM Operating Margin | 24.6% | 43.0% | 26.2% | 34.9% | 23.8% |
| LTM FCF Margin | 16.5% | -0.1% | 20.3% | 20.3% | 31.9% |
| 12M Market Return | -4.5% | 21.7% | 22.3% | -11.7% | -11.5% |
Why does this matter? PFE just went down -4.9% in a month – peer comparison puts stock performance, valuation, and financials in context – highlighting whether it is truly outperforming, lagging behind, and above all – can this continue? Read Buy or Sell PFE Stock to see if Pfizer is really a falling knife.
Revenue Growth Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| PFE | 3.9% | 6.8% | -41.1% | 24.5% |
| LLY | 36.8% | 32.0% | 19.6% | 0.8% |
| JNJ | 5.1% | 4.3% | 6.5% | 1.6% |
| MRK | 1.7% | 6.7% | 1.4% | 21.7% |
| BMY | 1.3% | 7.3% | -2.5% | -0.5% |
Operating Margin Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| PFE | 24.6% | 23.3% | 7.1% | 36.7% |
| LLY | 43.0% | 38.9% | 31.6% | 30.3% |
| JNJ | 26.2% | 24.9% | 27.5% | 26.3% |
| MRK | 34.9% | 31.5% | 4.9% | 30.8% |
| BMY | 23.8% | 12.2% | 18.2% | 19.7% |
PE Ratio Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| PFE | 14.1 | 18.7 | 76.7 | 9.2 |
| LLY | 61.0 | 65.7 | 100.1 | 52.8 |
| JNJ | 17.9 | 24.8 | 11.3 | 25.8 |
| MRK | 11.2 | 14.7 | 757.8 | 19.3 |
| BMY | 15.7 | -12.8 | 13.2 | 24.2 |
While peer comparison is critical, the Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.